Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $30.6 million.

  • Amicus Therapeutics' Change in Accured Expenses rose 31684.37% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.6 million, marking a year-over-year increase of 126839.78%. This contributed to the annual value of -$16.5 million for FY2024, which is 13358.06% down from last year.
  • Amicus Therapeutics' Change in Accured Expenses amounted to $30.6 million in Q3 2025, which was up 31684.37% from $10.4 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Change in Accured Expenses ranged from a high of $37.2 million in Q2 2022 and a low of -$40.2 million during Q1 2021
  • For the 5-year period, Amicus Therapeutics' Change in Accured Expenses averaged around $4.1 million, with its median value being $6.4 million (2021).
  • In the last 5 years, Amicus Therapeutics' Change in Accured Expenses surged by 120426.83% in 2021 and then plummeted by 3390416.67% in 2024.
  • Over the past 5 years, Amicus Therapeutics' Change in Accured Expenses (Quarter) stood at $29.5 million in 2021, then crashed by 207.95% to -$31.8 million in 2022, then skyrocketed by 125.42% to $8.1 million in 2023, then tumbled by 162.23% to -$5.0 million in 2024, then skyrocketed by 708.04% to $30.6 million in 2025.
  • Its Change in Accured Expenses stands at $30.6 million for Q3 2025, versus $10.4 million for Q2 2025 and $3.6 million for Q1 2025.